PATHWAY-27 PARTNERS

Italy
- Alma Mater Studiorum Università di Bologna (UNIBO) – PROJECT COORDINATOR
- European Commission - Joint Research Centre–Institute for Health and Consumer Protection (JRC)
- Giotto Biotech s.r.l. (GIO)
- NGB Genetics srl (NGB)

France
- Institut National de la Recherche Agronomique (INRA)
- Centre de Recherche en Nutrition Humaine Auvergne (CRNH)
- Applications Sante des Lipides (ASL)

Sweden
- Karolinska Institutet (KI)
- Swedish Oat Fiber (SOF)

Germany
- Max Rubner-Institut (MRI)
- Deutsches Krebsforschungszentrum (DKFZ)

Finland
- VTT Technical Research Centre of Finland (VTT)

United Kingdom
- University of Leeds (ULE)
- Leeds Teaching Hospital NHS (LTHT)
- International Food Network Ltd (IFN)

Denmark
- University of Southern Denmark (SDU)

Spain
- Asociación de Investigación de la Industria Agroalimentaria (AINIA)
- Abro Biotec,S.L. (ABRO)
- Grupo Desarrollo (DPL)

Turkey
- Ege University (EGE)

Hungary
- Campden BRI Magyarország Nonprofit Korlátolt Felelősségű Társaság (CBHU)
- AdWare Research Fejleszto es Tanacsado Kft. (ADWR)
- Adexgo Ipari Kereskedelmi és Szolgáltató Kft. (ADX)

Belgium
- International Life Sciences Institute Europe - aisbl (ILSI)

Austria
- Lebensmittelversuchsanstalt (LVA)

CONTACT

Dr. Alessandra Bordoni
(project coordinator)

Alma Mater Studiorum – University of Bologna
E-mail: alessandra.bordoni@unibo.it

www.pathway27.eu

PATHWAY-27 (FP7-KBBE.2012.2.2-01) is a collaborative project targeted to SMEs and financed by the European Commission's 7th Framework Programme, contract number 311876.

PATHWAY-27

PIVOTAL ASSESSMENT OF THE EFFECTS OF BIOACTIVES ON HEALTH AND WELLBEING. FROM HUMAN GENOMA TO FOOD INDUSTRY.

www.pathway27.eu

WHAT IS PATHWAY-27?

Project title:
"Pivotal Assessment of The effects of bioactives on Health and Wellbeing. From human genoma to food industry"

Project acronym:
PATHWAY-27

Funding:
EU FP7 funded research project

Acting Coordinator:
University of Bologna

Overall goal:
Systematic study of beneficial effects of bioactive-enriched foods in humans and roadmap for healthy food innovation in line with European legislation.

Number of Partners:
25

Project duration:
01/02/2013 - 31/01/2018

OBJECTIVES

General:
PATHWAY-27 explores selected bioactive compounds as ingredients of foods that, within the common diet, could significantly benefit human health and wellbeing. Three model compounds (docosahexaenoic acid - DHA, beta-glucan - BG, and anthocyanins - AC) and three model food matrices (bakery, dairy and egg products) are being studied to derive widely applicable conclusions.

Scientific:
PATHWAY-27 aims to better understand the potential benefits and mechanism of action of the three bioactive compounds DHA, BG and AC as ingredients of bioactive-enriched foods, in the prevention of the Metabolic Syndrome.

Technological:
PATHWAY-27 strives to develop improved food formulations that lead to the production of bioactive-enriched foods with a scientifically demonstrated impact on health.

IMPACT OF PATHWAY-27

PATHWAY-27 will deliver a better understanding of the role and mechanism/s of action of specific bioactives as food ingredients. The project will also define a generic roadmap that can be followed while demonstrating the effects of all types of bioactives and foods enriched with them.

- **Increased knowledge** on availability, activity, synergism and mechanisms of action of **bioactive compounds** when administered as **integral parts of foods.**
- **Guidelines and best practice** for undertaking dietary **intervention studies** using bioactive ingredients as well as developing and validating **innovative biomarkers** that are relevant to humans.
- **Increase** in the innovation potential and **competitiveness** of **SMEs**.
- **Supporting** the implementation of European **legislation on health and nutrition claims.**